Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | NPY2R | P49146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475027 | 0.86 | HSD17B10 (0.39) | CYP2D6LMNAALDH1A1 | |
| SCHEMBL28965487 | 0.81 | NR1H2 (0.33) | CYP2D6KCNH2HRH3HSD11B1 | |
| SCHEMBL4476428 | 0.79 | CYP2D6 (0.38) | CYP2D6KCNH2HRH3HSD11B1LMNA | |
| SCHEMBL28619555 | 0.76 | DRD2 (0.46) | LMNAALDH1A1 | |
| SCHEMBL5765556 | 0.74 | CYP2D6 (0.55) | CYP2D6KCNH2HRH3HSD11B1LMNA | |
| SCHEMBL28405167 | 0.73 | LMNA (0.36) | CYP2D6KCNH2HRH3HSD11B1LMNA | |
| SCHEMBL28703415 | 0.73 | PAOX (0.35) | CYP2D6KCNH2HRH3HSD11B1ALDH1A1 | |
| SCHEMBL18682741 | 0.73 | HTT (0.30) | — | |
| Hydrochloric Acid SCHEMBL29034671 | 0.72 | CYP2D6 (0.53) | CYP2D6KCNH2HRH3HSD11B1LMNA | |
| SCHEMBL3997166 | 0.72 | GNAO1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538111-B2 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2009-05-26 | — | — | US | disclosed |
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LABORATOIRES FOURNIER S.A. (FR) | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178360-A1 | Benzenesulphonamide derivatives, method for production and use thereof for treatment of pain | LTB4R2, BDKRB2, TBXA2R | CYP2D6 59/4885KCNH2 464/4885HRH3 863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.